Tag: treatments

SUNNYVALE, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that Henry Ford Health in Detroit, Michigan is now enrolling patients with ischemic HFrEF in the Company’s ongoing pivotal CardiAMP HF II trial.

BETHESDA, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase common stock in an underwritten public offering. Gain expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock and/or the warrants offered in the offering. All of the securities are being offered by the Company.

Following successful SCC audit, CNL is ready to perform pre-clinical studies for growing radiopharmaceutical industry as GLP-compliant laboratory

Cardiff, United Kingdom – 15 July 2025 – Draig Therapeutics (“Draig”), a clinical-stage company aiming to transform the treatment of neuropsychiatric diseases, today announces the appointment of Douglas E. Williams, Ph.D. as independent Chair of its Board of Directors. He takes over from Ruth McKernan, who retains her role on the Board as a Director and Interim Chief Executive Officer (CEO).

SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company dedicated to advancing patient care through transformative urology solutions, today announced that Aquablation therapy was assigned a Category I code effective January 1, 2026.